(:IDRA)

Jan 17, 2023 08:00 am ET
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA), a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the Company has changed its name and...
Nov 14, 2022 04:05 pm ET
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. “We are pleased to have completed the...
Sep 28, 2022 04:09 pm ET
Idera Pharmaceuticals Acquires Aceragen
Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today announced it has completed the acquisition of Aceragen, Inc. (“Aceragen”), a privately-held biotechnology company addressing rare, orphan pulmonary and...
Aug 09, 2022 04:15 pm ET
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results
Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022. Second Quarter Financial Results Our cash position as of...
May 17, 2022 10:53 am ET
Healthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and Glaucoma
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Brickell Biotech (NASDAQ: BBI), Idera Pharmaceuticals...
May 17, 2022 10:30 am ET
Thinking about buying stock in Annaly Capital Management, Idera Pharmaceuticals, REE Automotive, Applied UV, or AgriFORCE Growing Systems?
NEW YORK, May 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NLY, IDRA, REE, AUVI, and AGRI.
May 17, 2022 08:04 am ET
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving...
May 05, 2022 04:15 pm ET
Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2022. “We continue to preserve cash while actively pursuing new...
Mar 31, 2022 04:15 pm ET
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2021. “We are actively identifying and evaluating new...
Jan 18, 2022 07:35 am ET
Thinking about buying stock in Surgalign, Pluristem Therapeutics, Houghton Mifflin Harcourt, Idera Pharmaceuticals, or Vinco Ventures?
NEW YORK, Jan. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRGA, PSTI, HMHC, IDRA, and BBIG.
Dec 14, 2021 04:32 pm ET
Idera Pharmaceuticals Announces Tilsotolimod Updates
Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist. ILLUMINATE-206 Trial for the Treatment of Previously...
Nov 08, 2021 04:14 pm ET
Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2021. “We are maintaining our focus on identifying new...
Aug 09, 2021 04:15 pm ET
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021. “Our goal is to add new development or commercial-stage assets to Idera’s...
Jun 23, 2021 10:45 am ET
Thinking about buying stock in Entera Bio, Torchlight Energy, Idera Pharmaceuticals, Nikola Corp, or Orphazyme?
NEW YORK, June 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENTX, TRCH, IDRA, NKLA, and ORPH.
Jun 22, 2021 09:31 am ET
Thinking about buying stock in Biocept, Histogen, Idera Pharmaceuticals, Satsuma Pharmaceuticals, or Clover Health Investments?
NEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, HSTO, IDRA, STSA, and CLOV.
May 18, 2021 04:15 pm ET
Idera Pharmaceuticals Announces Corporate Updates
Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1...
Apr 29, 2021 04:10 pm ET
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2021. “Despite the disappointing objective response rate (ORR) results from...
Mar 18, 2021 04:15 pm ET
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory...
Mar 01, 2021 04:35 pm ET
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020. “Tilsotolimod is the most advanced TLR-9 agonist therapy in...
Jan 11, 2021 06:02 am ET
Idera Pharmaceuticals to Present at Upcoming Conferences
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. “2021 represents a pivotal inflection point for Idera, one in which we anticipate that data soon to be available...
Dec 15, 2020 08:05 am ET
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Purchase Agreement”), resulting in aggregate proceeds of up to $20.7 million in common stock and...
Nov 17, 2020 04:27 pm ET
Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; “Idera”) today announced that Daniel Soland will join Idera on January 4, 2021, as Senior Vice President and Chief Operating Officer (COO). Mr. Soland has been engaged as a consultant to Idera for nearly...
Oct 29, 2020 04:36 pm ET
Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2020. “Tilsotolimod is the most advanced TLR-9 agonist therapy in development, and...
Sep 28, 2020 08:45 am ET
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907 Patent) and allowed U.S. Patent Application No. 16/557,597 (the ‘597 Application), both entitled...
Sep 15, 2020 07:18 am ET
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that final data from the ILLUMINATE-204 trial investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist, will be presented in a Mini...
Aug 04, 2020 04:10 pm ET
Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2020. “Idera meaningfully advanced its clinical pipeline and strengthened its...
Jul 20, 2020 09:31 am ET
Thinking about buying stock in iBio Inc, Idera Pharmaceuticals, PDS Biotechnology, Checkpoint Therapeutics, or Norwegian Cruise Line Holdings?
NEW YORK, July 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, IDRA, PDSB, CKPT, and NCLH.
Jul 15, 2020 08:05 am ET
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for a private placement exempt from the registration requirements of the Securities Act of 1933, as...
Jun 02, 2020 08:15 am ET
Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of  ILLUMINATE-206, a Phase 2, open-label, multi-center study to evaluate tilsotolimod in combination with...
May 01, 2020 08:00 am ET
Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders
Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today provided notice of a change in the location for its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) via the filing of additional proxy materials with the U.S....
Apr 30, 2020 04:35 pm ET
Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2020. “I’m proud of what Idera has accomplished since the beginning of the year,...
Apr 23, 2020 07:30 am ET
Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020
Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist, will be...
Apr 21, 2020 07:30 am ET
Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (the Company) today is announcing final topline data from the ILLUMINATE-204 trial investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist. ILLUMINATE-204 is...
Apr 07, 2020 04:05 pm ET
Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with an institutional investor providing for a private placement exempt from the registration requirements of the Securities Act of 1933,...
Mar 12, 2020 07:30 am ET
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA) reported on March 11, 2020 its financial and operational results for the fourth quarter and year ended December 31, 2019. “In 2019, we made great progress with ILLUMINATE-301, our registrational...
Mar 05, 2020 07:00 am ET
Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma
Idera Pharmaceuticals, Inc. (“Idera” or “the company”) (NASDAQ: IDRA) today announced completion of patient enrollment into ILLUMINATE-301, its registrational trial of tilsotolimod in combination with ipilimumab in patients with anti-PD-1...
Jan 14, 2020 07:00 am ET
Idera Pharmaceuticals Provides 2020 Update and Outlook
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or Idera or the Company, today is providing an update on its tilsotolimod clinical development program and providing a corporate outlook for 2020. “We made tremendous progress last year with the...
Dec 23, 2019 09:15 am ET
Idera Pharmaceuticals Announces Private Placement Up To $97.7 Million
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional investor providing for a private placement exempt from the registration requirements of the...
Nov 06, 2019 04:01 pm ET
Idera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial Results
Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications, today...
Oct 21, 2019 07:00 am ET
Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019 U.S. Patent No. 10,10,463,686 entitled “Immune Modulation With TLR9 Agonists For Cancer Treatment,”...
Sep 30, 2019 07:30 am ET
Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a toll-like receptor 9 (TLR9) agonist, in combination with nivolumab, a programmed death receptor-1...
Sep 04, 2019 07:00 am ET
Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie, a global, research-based biopharmaceutical company.  The purpose of the collaboration is to...
Aug 30, 2019 12:00 pm ET
Idera Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the Baird 2019 Global Healthcare Conference on Wednesday, September 4, 2019 at 8:30 a.m. Eastern Time at the InterContinental New York Barclay Hotel. A...
Aug 08, 2019 09:00 am ET
Idera Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2019 Financial Results
Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications, today...
Aug 06, 2019 04:00 pm ET
Idera to Release 2019 Second Quarter Results on August 8, 2019
Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications, today...
Jul 23, 2019 07:30 am ET
Idera Pharmaceuticals Announces Appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and John J. Kirby as Chief Financial Officer
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and the promotion of John J. Kirby to Chief Financial Officer. Dr. Tarka was most recently the Vice President of...
Jun 18, 2019 04:00 pm ET
Idera Pharmaceuticals to Present at the 2019 JMP Securities Life Sciences Conference
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 2019 JMP Securities Life Sciences Conference on Thursday, June 20, 2019 at 1:30 p.m. Eastern Time at the St. Regis Hotel in New York City.  A live...
May 02, 2019 04:30 pm ET
Idera Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications, today...
Apr 12, 2019 08:40 am ET
Report: Developing Opportunities within World Wrestling Entertainment, Adient, Synaptics, WidePoint, Silvercrest Asset Management Group, and Idera Pharmaceuticals — Future Expectations, Projections Mo
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of World Wrestling Entertainment, Inc. (NYSE:WWE), Adient PLC (NYSE:ADNT),...
Apr 10, 2019 07:00 am ET
Idera Pharmaceuticals Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology and rare disease indications, today announced...
Apr 02, 2019 07:00 am ET
Idera Pharmaceuticals Presents ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors at the American Association
Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology and rare disease indications, today is...
Mar 06, 2019 04:30 pm ET
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications...
Feb 27, 2019 07:00 am ET
Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor T
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced completion of enrollment into the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in...
Jan 04, 2019 07:30 am ET
Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Westin St....
Dec 18, 2018 04:05 pm ET
Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Carol A. Schafer joined its Board of Directors, effective December 18, 2018.  Ms. Schafer is a seasoned financial professional with more than 25 years of experience in investment...
Dec 14, 2018 07:00 am ET
Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Fai
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today is presenting data from the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with...
Dec 12, 2018 04:01 pm ET
Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined...
Dec 11, 2018 07:20 am ET
United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mercer International Inc. (NASDAQ:MERC), United Parcel Service, Inc....
Nov 06, 2018 04:30 pm ET
Idera Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications characterized by...
Oct 19, 2018 06:00 am ET
Idera Pharmaceuticals Presents Data from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatmen
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined...
Oct 15, 2018 07:55 am ET
Report: Developing Opportunities within Callon Petroleum, National Oilwell Varco, GameStop, Papa John's International, Baker Hughes, a GE company, and Idera Pharmaceuticals — Future Expectations, Proj
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Callon Petroleum Company (NYSE:CPE), National Oilwell Varco, Inc....
Sep 18, 2018 04:01 pm ET
Idera Pharmaceuticals Announces Appointment of Howard Pien to its Board of Directors
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that Howard Pien joined its Board...
Sep 11, 2018 07:00 am ET
Idera Pharmaceuticals Announces Corporate Organizational Changes
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced several organization updates.  The...
Aug 30, 2018 07:30 am ET
Idera Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that the company will participate...
Aug 14, 2018 07:35 am ET
Research Report Identifies Acushnet, Capitol Federal Financial, Laredo Petroleum, Intrexon, Corning, and Idera Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acushnet Holdings Corp. (NYSE:GOLF), Capitol Federal Financial...
Aug 09, 2018 07:00 am ET
Idera Pharmaceuticals To Present at the 2018 Wedbush PacGrow Healthcare Conference
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that the company will participate...
Aug 02, 2018 04:30 pm ET
Idera Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today reported its financial and operational...
Jul 27, 2018 11:58 am ET
Idera Pharmaceuticals Announces One-for-Eight Reverse Stock Split
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that its Board of Directors has...
Jul 16, 2018 07:00 am ET
Idera Pharmaceuticals Provides Update on Corporate Strategy and Outlook
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, is providing an update on the company’s corporate...
Jul 10, 2018 04:01 pm ET
Idera Pharmaceuticals Announces Termination of Merger Agreement with BioCryst Pharmaceuticals
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced today that the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into by and among Idera and BioCryst on January 22, 2018, has been terminated.  The Merger Agreement...
Jun 20, 2018 04:20 pm ET
Great Point Partners, LLC Remains Opposed To The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc.
GREENWICH, Conn., June 20, 2018 /PRNewswire/ -- Great Point Partners, LLC ("GPP") today submitted a letter to the Board of Directors of BioCryst Pharmaceuticals, Inc. ("BCRX") expressing its continued opposition to BCRX's proposed merger with Idera Pharmaceuticals, Inc. The full text of the letter can be found below and is attached as an exhibit to GPP's Schedule 13D, which was filed today.
Jun 13, 2018 07:00 am ET
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018 at 10:00 A.M....
Jun 12, 2018 07:30 am ET
Idera Pharmaceuticals Reports Results from Phase 2 Trial of IMO-8400 in Dermatomyositis
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, today announced topline results from the Phase 2 clinical...
Jun 04, 2018 07:30 am ET
Idera Pharmaceuticals Presents Clinical Data from the ILLUMINATE-204 Trial of the Combination of tilsotolimod and ipilimumab for Anti-PD-1 Refractory Metastatic Melanoma at the 2018 American Society o
The combination regimen is generally well tolerated and no synergistic toxicity was observed - EXTON, Pa., June 04, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing...
May 24, 2018 06:00 am ET
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 8:30...
May 16, 2018 07:55 am ET
New Research Coverage Highlights Tyson Foods, Windstream, Laredo Petroleum, Idera Pharmaceuticals, Diamondrock Hospitality, and Organovo — Consolidated Revenues, Company Growth, and Expectations for 2
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tyson Foods, Inc. (NYSE:TSN), Windstream Holdings, Inc. (NASDAQ:WIN),...
May 09, 2018 07:00 am ET
Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its...
Apr 26, 2018 07:00 am ET
Apr 17, 2018 07:00 am ET
Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 20
Triple combination of tilsotolimod (IMO-2125), epacadostat (IDO-1) and anti-PD-1 antibody demonstrate maximal anti-tumor efficacy in pre-clinical models
Apr 10, 2018 07:30 am ET
BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (“BioCryst”) and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera”) today jointly announced that they have each rescheduled their respective Special Meetings of Stockholders (each, a “Special Meeting”) to vote on the proposed merger of BioCryst and Idera to July 10, 2018 at 10:00 AM ET.
Apr 02, 2018 08:00 am ET
Mar 22, 2018 12:00 pm ET
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., March 22, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced they will be presenting at the 17th Annual Needham Healthcare Conference on...
Mar 07, 2018 07:30 am ET
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
EXTON, Pa. and CAMBRIDGE, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today...
Mar 01, 2018 07:00 am ET
Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)
- Clinical trial targeting enrollment of approximately 300 anti-PD-1 refractory melanoma patients at approximately 80 global trial sites - 
Feb 27, 2018 08:00 am ET
BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger
Provide Update on Key Benefits of Pending Merger and Comprehensive Evaluation of Strategic Opportunities Leading Up to Definitive Merger Agreement
Feb 19, 2018 01:00 pm ET
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., Feb. 19, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), today announced they will be presenting at two upcoming healthcare-focused investor conferences.
Feb 02, 2018 08:15 am ET
Investor Expectations to Drive Momentum within Hurco Companies, L.B. Foster, Upland Software, Idera Pharmaceuticals, United Parcel Service, and Geron — Discovering Underlying Factors of Influence
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hurco Companies, Inc. (NASDAQ:HURC), L.B. Foster...
Jan 30, 2018 10:25 am ET
RM LAW Announces Investigation of Idera Pharmaceuticals, Inc.
BERWYN, Pa., Jan. 30, 2018 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of Idera Pharmaceuticals, Inc. ("Idera" or the "Company") (NASDAQ: IDRA) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to BioCryst Pharmaceuticals, Inc.
Jan 22, 2018 02:52 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Idera Pharmaceuticals, Inc. - IDRA
NEW YORK, Jan. 22, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors and Officers of Idera Pharmaceuticals, Inc. ("Idera" or the "Company") (NasdaqCM: IDRA) for possible breaches of fiduciary duty.
Jan 22, 2018 01:20 pm ET
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Idera Pharmaceuticals, Inc. (IDRA) on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) stockholders concerning the proposed merger of the company with BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX).
Jan 22, 2018 08:30 am ET
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases
Filed by BioCryst Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12Under the Securities Exchange Act of 1934Subject Company: Idera Pharmaceuticals, Inc.Commission File No. of Subject Company: 001-31918
Jan 05, 2018 07:00 am ET
Idera Pharmaceuticals Provides 2018 Update and Outlook
Company to Present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 11:00 AM PT/2:00 PM ET
Nov 28, 2017 08:00 am ET
Analysis: Positioning to Benefit within Kirby, AmerisourceBergen, Celgene, Sabre, Noble Energy, and Idera Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 28, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kirby Corporation (NYSE:KEX), AmerisourceBergen Corporation (Holding...
Nov 27, 2017 04:01 pm ET
Idera to Present at the 29th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass. and EXTON, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that the company will...
Nov 09, 2017 07:30 am ET
Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)
- Available Translational Data Continue to Demonstrate Correlation between Proliferation and Clonal Expansion of T-Cells to Clinical Responses -
Nov 06, 2017 04:02 pm ET
Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
– IMO 2125 Translational Data Update at SITC on November 11 –– Completes Public Offering, extends runway into second quarter 2019 –...
Nov 06, 2017 04:02 pm ET
Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
– IMO 2125 Translational Data Update at SITC on November 11 –– Completes Public Offering, extends runway into second quarter 2019 –
Oct 24, 2017 04:01 pm ET
Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. and EXTON, Pa, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced that it intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering. In connection with this offering, Idera expects to grant the underwriters a 30-day option to purchase additional shares of common stock, in an amount equal to up to 15% of the number of shares of common stock sold in the offering. All of the shares in the offering are to be sold by Idera. Idera intends to use the net proceeds f...
Oct 24, 2017 04:01 pm ET
Idera Pharmaceuticals Provides Corporate Governance Update
CAMBRIDGE, Mass. and EXTON, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Youssef El Zein, Managing Partner of Pillar Invest Corporation has elected to step down from the company’s Board of Directors, effective immediately.  Mr. El Zein has served as a member of Idera’s Board of Directors since 1992 and during that time has displayed tremendous passion, energy and strategic influence as well as playi...
Sep 10, 2017 08:15 am ET
Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate (ORR) of 44% in Melanoma Patients Refractory to Ant
CAMBRIDGE, Mass. and EXTON, Pa., Sept. 10, 2017 /PRNewswire/ -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, today announced final results from the dose-selection phase of an ongoing Phase 1/2 trial investigating IMO-2125, Idera's intratumorally-delivered Toll-like Receptor (TLR) 9 agonist, in combination with ipilimumab (Yervoy®), manufactured by Bristol-Myers Squibb. These data were presented at the 2017 European Society for Medical Oncology Congres
May 04, 2017 04:01 pm ET
Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. and EXTON, Pa., May 04, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the first quarter ended March 31, 2017....
Apr 18, 2017 04:01 pm ET
Idera Pharmaceuticals Announces Organizational Update
CAMBRIDGE, Mass. and EXTON, Pa., April 18, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Sudhir Agrawal, D. Phil, the company’s President of Research and member of the company’s Board of Directors, plans to retire on May 31, 2017.  However, Dr. Agrawal will continue to contribute to the company as a scientific advisor....
Mar 28, 2017 09:30 am ET
Mar 15, 2017 04:30 pm ET
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update
- IMO-2125 Confirmed Responses in PD-1 Refractory Melanoma Appear Durable -...
Mar 02, 2017 07:30 am ET
Idera to Present at the 37th Annual Cowen and Company Health Care Conference
CAMBRIDGE, Mass. and EXTON, Pa., March 02, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera’s Chief Medical Officer, Joanna Horobin, M.B., Ch.B. will provide a corporate overview and update at the 37th Annual Cowen and Company Health Care Conference on Wednesday, March 8, 2017 at 11:20 a.m. Eastern Time at the Boston Marriott Copley Place....
Feb 06, 2017 08:00 am ET
Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development
CAMBRIDGE, Mass. and EXTON, Pa., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced the appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development.  Dr. Yingling was most recently the Chief Scientific Officer of Bind Therapeutics, Inc., and had previously served as Vice President of Oncology Discovery and Translational Research at Bristol Myers Squibb and Company.  In this newly created...
Nov 28, 2016 07:00 am ET
Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IMO-9200
CAMBRIDGE, Mass., EXTON, Pa. and HAMILTON, Bermuda, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), and Vivelix Pharmaceuticals, Ltd. today announced that they have entered into an exclusive license and collaboration agreement granting Vivelix worldwide rights to develop and market IMO-9200, an antagonist of TLR 7,8 and 9, for non-malignant gastrointestinal disorders.  As part of the agreement, Idera has agreed to create and characterize potential back-up compounds for Vivelix....
Nov 11, 2016 03:15 pm ET
Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125 from Ongoing Phase 1 Dose Escalation in Clinical Trial in Combination with Ipilimumab in Me
CAMBRIDGE, Mass. and EXTON, Pa., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, is reporting translational data supporting the mechanism of action of intratumoral IMO-2125, a Toll-like receptor (TLR) 9 agonist from the ongoing Phase 1 dose escalating clinical trial.  In this trial, IMO-2125 is being evaluated in combination with ipilimumab for treatment of patients with metastatic melanoma with disease that is refractory to ...
Oct 28, 2016 07:30 am ET
Idera Pharmaceuticals Reports Third Quarter 2016 Financial Results
CAMBRIDGE, Mass. and EXTON, Pa., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the third quarter ended September 30, 2016....
Oct 05, 2016 04:00 pm ET
Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. and EXTON, Pa., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced that it intends to offer and sell up to $50,000,000 of shares of its common stock in an underwritten public offering. In connection with this offering, Idera expects to grant the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. All of the shares in the offering are to be sold by Idera. Idera intends to use the net proceeds from this o...
Sep 27, 2016 07:30 am ET
Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society
CAMBRIDGE, Mass. and EXTON, Pa., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced the presentations of new pre-clinical data on the mechanism of action supporting selective targeting of single point mutations.  Also, data was presented on 3GA targeting the NLRP3 gene for the treatment of inflammatory disorders....
Sep 26, 2016 07:00 am ET
Aug 24, 2016 07:00 am ET
Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense Technology
CAMBRIDGE, Mass. and EXTON, Pa., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced the presentation of new pre-clinical data that demonstrates the novel gene-silencing mechanism of action of the third generation antisense (3GA) technology platform....
Aug 12, 2016 09:30 am ET
Idera to Present at the 2016 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass. and EXTON, Pa., Aug. 12, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera’s Chief Executive Officer, Vincent Milano will provide a corporate overview and participate in a fireside chat discussion at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 12:45 p.m. Eastern Time at the Le Parker Meridien Hotel in New York City....
Aug 02, 2016 07:00 am ET
Idera Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. and EXTON, Pa., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the second quarter ended June 30, 2016....
Jun 07, 2016 09:00 am ET
Idera to Present at Two June Investor Healthcare Conferences
CAMBRIDGE, Mass. and EXTON, Pa., June 07, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera’s Chief Medical Officer, Joanna Horobin, M.B., Ch.B. will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 4:00 p.m. Eastern Time at the Grand Hyatt in New York City....
May 09, 2016 04:00 pm ET
Idera Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
9 of 10 Waldenstrom’s Macroglobulinemia Patients Treated at the Highest Dose have Demonstrated Reductions in IgM or M-Protein Levels in Ongoing Trial...
May 05, 2016 07:30 am ET
Idera to Release 2016 First Quarter Results on May 9, 2016
CAMBRIDGE, Mass. and EXTON, Pa., May 05, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced that first quarter results for 2016 are expected to be released on Monday, May 9, 2016 after the close of the U.S. Financial Markets....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.